Q-omics provides the consensus-scored SCN3B profile across patient tissues and cancer cell-line models. SCN3B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, SCN3B is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, SCN3B RNA expression shows 17,559 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUSC, THCA, and GBM as cancer lineages where SCN3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCN3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCN3B survival associations across molecular data types. SCN3B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCN3B RNA expression–survival associations across cancer types. High SCN3B expression shows unfavorable associations in LUSC and BLCA, but favorable associations in LGG, KIRC, PAAD and UCS. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for SCN3B RNA expression.
This table summarizes SCN3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SCN3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCN3B shows lower tumor expression in THCA, COAD, UCEC, BRCA, KICH and LUSC. The THCA box plot shows higher SCN3B RNA expression in normal versus tumor tissue (log2 FC = −1.557, t-test p < 0.001).
This table shows molecular features associated with SCN3B in patient tissues and cancer cell lines. In patient samples, SCN3B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SCN3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
